TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
FHTX

Foghorn Therapeutics Inc

Healthcare · Biotechnology

2.10$ -0.5% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Foghorn Therapeutics Inc (FHTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 43.1% of the shares are freely tradable; institutional investors hold 76.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 76.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 17.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 43.1%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 6.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 59Mio.

Largest Shareholders

Institutions

Institutions FHTX
Name Stake (%) Shares Change (%) Date
Flagship Ventures Management, Inc. 21.34 12,674,120 +0.0 06/30/2026
Bvf Inc 9.84 5,842,000 +0.0 06/30/2026
FMR Inc 9.61 5,705,958 -5.6 06/30/2026
Deerfield Management Co 7.40 4,394,367 +0.0 06/30/2026
BlackRock Inc 4.42 2,626,832 +11.1 06/30/2026
Euclidean Capital LLC 2.65 1,573,761 +0.0 06/30/2026
Vanguard Capital Management, LLC 2.52 1,494,611 +0.0 06/30/2026
Geode Capital Management, LLC 1.53 910,866 +7.4 06/30/2026

Funds

Funds FHTX
Name Stake (%) Shares Change (%) Date
Fidelity Growth Company Fund 3.09 1,834,180 +0.0 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 1.88 1,118,679 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?